EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05)

Chen Li, Yantao Tian, Yanan Zheng, Fei Yuan, Zheng Shi, Lin Yang, Hao Chen, Lixin Jiang, Xixun Wang, Ping Zhao, Benyan Zhang, Zhenqiang Wang und 29 weitere

Journal of Clinical Oncology · 2025-02 · 43 (4) · 464-474

DOI: 10.1200/jco.24.00795 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025-02. Verfasst von Chen Li und 40 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Adenocarcinoma, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Stomach Neoplasms. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE This multicenter, randomized phase III trial evaluated the efficacy and safety of perioperative camrelizumab (an anti–PD-1 antibody) plus low-dose rivoceranib (a VEGFR-2 inhibitor) and S-1 and oxaliplatin (SOX) (SOXRC), high-dose rivoceranib plus SOX (SOXR), and SOX alone (SOX) for locally advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. METHODS Patients with T3-4aN + M0 G/GEJ adenocarcinoma were randomly assigned (1:1:1) to receive perioperative treatment with SOXRC, SOXR, or SOX. The primary end points were pathologic complete response (pCR) and event-free survival. The Independent Data Monitoring Committee recommended stopping enrollment in the SOXR group on the basis of the safety data of the first 103 randomly assigned patients in the three groups. The patients were then randomly assigned 1:1 to the SOXRC or SOX groups. This report presents the pCR results obtained per protocol for the first 360 randomly assigned patients who had the opportunity for surgery in the SOXRC and SOX groups. RESULTS In the SOXRC and SOX groups, of the 180 patients in each group, 99% and 98% of patients received neoadjuvant therapy, 91% and 94% completed planned neoadjuvant therapy, and 86% and 87% underwent surgery, respectively. The pCR was significantly higher in the SOXRC group at 18.3% (95% CI, 13.0 to 24.8) compared with 5.0% (95% CI, 2.3 to 9.3) in the SOX group (difference of 13.7%; 95% CI, 7.2 to 20.1; odds ratio of 4.5 [95% CI, 2.1 to 9.9]). The one-sided P value was

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsStomach NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedDrug CombinationsEsophagogastric JunctionNeoadjuvant TherapyOxaliplatinOxonic AcidPerioperative CarePathologic Complete ResponseTegafur

Substanzen

Antibodies, Monoclonal, HumanizedcamrelizumabDrug CombinationsOxaliplatinOxonic AcidS 1 (combination)Tegafur

Autor:innen und Institutionen

  • Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
  • Pancreatogastric Surgery, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
  • Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
  • Gastrointestinal Surgery, Shanghai Changhai Hospital, Shanghai, China.
  • Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
  • Oncological Surgery, Lanzhou University Second Hospital, Lanzhou, China.

ORCID-Profile: Heli Liu, Zhenggang Zhu

Zitieren

APA

Li, C., Tian, Y., Zheng, Y., Yuan, F., Shi, Z., Yang, L., Chen, H., Jiang, L., Wang, X., Zhao, P., Zhang, B., Wang, Z., Zhao, Q., Dong, J., Lian, C., Xu, S., Zhang, A., Zheng, Z., Wang, K., …, & Zhu, Z. (2025). Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05). Journal of Clinical Oncology, 43(4), 464-474. https://doi.org/10.1200/jco.24.00795

Vancouver

Li C, Tian Y, Zheng Y, Yuan F, Shi Z, Yang L, et al. Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05). Journal of Clinical Oncology. 2025;43(4):464-474. doi:10.1200/jco.24.00795

BibTeX
@article{Li2025,
  author = {Li, Chen and Tian, Yantao and Zheng, Yanan and Yuan, Fei and Shi, Zheng and Yang, Lin and Chen, Hao and Jiang, Lixin and Wang, Xixun and Zhao, Ping and Zhang, Benyan and Wang, Zhenqiang and Zhao, Qun and Dong, Jianhong and Lian, Changhong and Xu, Sanrong and Zhang, Aimin and Zheng, Zhichao and Wang, Kang and Dang, Chengxue and Wu, Dan and Chen, Jian and Xue, Yingwei and Liang, Bo and Cheng, Xiangdong and Wang, Qian and Chen, Luchuan and Xia, Tao and Liu, Heli and Xu, Dazhi and Zhuang, Jing and Wu, Tao and Zhao, Xi and Wu, Wei and Wang, Hongzhi and Peng, Junsheng and Hou, Zhiguo and Zheng, Rongrong and Chen, Yuting and Yin, Kai and Zhu, Zhenggang},
  title = {Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05)},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {4},
  pages = {464--474},
  doi = {10.1200/jco.24.00795}
}
Kostenlos starten →